Replimune Group (REPL) Competitors $5.81 -0.08 (-1.36%) Closing price 04:00 PM EasternExtended Trading$5.80 0.00 (-0.09%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. APGE, CDTX, BEAM, BHVN, TWST, IMCR, AUPH, TVTX, ARDX, and WVEShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Biohaven (BHVN), Twist Bioscience (TWST), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Ardelyx (ARDX), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Apogee Therapeutics Cidara Therapeutics Beam Therapeutics Biohaven Twist Bioscience Immunocore Aurinia Pharmaceuticals Travere Therapeutics Ardelyx WAVE Life Sciences Replimune Group (NASDAQ:REPL) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media favor REPL or APGE? In the previous week, Replimune Group had 24 more articles in the media than Apogee Therapeutics. MarketBeat recorded 34 mentions for Replimune Group and 10 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.22 beat Replimune Group's score of 0.26 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 5 Very Positive mention(s) 3 Positive mention(s) 23 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Apogee Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is REPL or APGE more profitable? Apogee Therapeutics' return on equity of -34.65% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% Apogee Therapeutics N/A -34.65%-32.76% Which has more risk & volatility, REPL or APGE? Replimune Group has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Do analysts recommend REPL or APGE? Replimune Group currently has a consensus target price of $6.50, indicating a potential upside of 11.88%. Apogee Therapeutics has a consensus target price of $97.29, indicating a potential upside of 162.01%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Apogee Therapeutics is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Do insiders & institutionals believe in REPL or APGE? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 42.8% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, REPL or APGE? Apogee Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.79Apogee TherapeuticsN/AN/A-$182.15M-$4.13-8.99 SummaryApogee Therapeutics beats Replimune Group on 9 of the 13 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$453.53M$3.12B$5.76B$9.90BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-1.7921.0283.0226.61Price / SalesN/A379.66502.90163.15Price / CashN/A43.5325.7028.92Price / Book1.358.1110.796.52Net Income-$247.30M-$53.35M$3.29B$266.21M7 Day Performance7.99%0.01%0.13%-0.77%1 Month Performance1.75%7.04%7.22%3.84%1 Year Performance-44.35%11.96%50.16%24.37% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.2226 of 5 stars$5.81-1.4%$6.50+11.9%-42.7%$453.53MN/A-1.79210Trending NewsGap DownAPGEApogee Therapeutics3.2064 of 5 stars$36.37-0.7%$97.29+167.5%-21.2%$1.68BN/A0.0091News CoveragePositive NewsCDTXCidara Therapeutics3.7132 of 5 stars$65.39+0.2%$64.14-1.9%+447.3%$1.66B$1.27M0.0090News CoverageBEAMBeam Therapeutics2.5377 of 5 stars$16.36-2.9%$48.45+196.2%-23.1%$1.66B$63.52M0.00510News CoveragePositive NewsBHVNBiohaven3.86 of 5 stars$15.35-1.1%$54.23+253.2%-57.5%$1.63BN/A-2.00239Trending NewsAnalyst ForecastTWSTTwist Bioscience3.8809 of 5 stars$26.97+1.4%$49.40+83.2%-36.5%$1.63B$312.97M0.00990Positive NewsIMCRImmunocore1.5482 of 5 stars$32.22-0.1%$56.89+76.6%-2.2%$1.62B$310.20M0.00320News CoverageAUPHAurinia Pharmaceuticals2.9877 of 5 stars$11.99-0.7%$12.00+0.1%+79.6%$1.58B$235.13M23.51300News CoveragePositive NewsTVTXTravere Therapeutics2.1682 of 5 stars$17.50-1.1%$33.43+91.0%+104.3%$1.56B$233.18M0.00460News CoverageAnalyst UpgradeAnalyst RevisionARDXArdelyx4.4885 of 5 stars$6.36-0.3%$11.50+80.8%+15.6%$1.53B$333.61M0.0090News CoveragePositive NewsAnalyst UpgradeWVEWAVE Life Sciences4.7375 of 5 stars$9.60-3.3%$20.27+111.1%+44.1%$1.53B$108.30M0.00240Trending NewsAnalyst Forecast Related Companies and Tools Related Companies Apogee Therapeutics Alternatives Cidara Therapeutics Alternatives Beam Therapeutics Alternatives Biohaven Alternatives Twist Bioscience Alternatives Immunocore Alternatives Aurinia Pharmaceuticals Alternatives Travere Therapeutics Alternatives Ardelyx Alternatives WAVE Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
